On March 28, 2024, we opened a consultation to gather feedback on aspects of our draft updated procedures for provisional funding algorithms. The original deadline of April 26, 2024, has now been extended to May 3, 2024. Read our announcement to access the draft procedures and for complete details on how to participate.
| Call for patient/clinician input open | 23-Apr-24 |
|---|---|
| Call for patient/clinician input closed | 17-Jun-24 |
| Submission received | 04-Jun-24 |
| Submission accepted | 18-Jun-24 |
| Review initiated | 19-Jun-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 05-Sep-24 |
| Deadline for sponsors comments | 16-Sep-24 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 10-Oct-24 |
| Expert committee meeting (initial) | 23-Oct-24 |
| Draft recommendation issued to sponsor | 05-Nov-24 |
| Draft recommendation posted for stakeholder feedback | 14-Nov-24 |
| End of feedback period | 28-Nov-24 |
| Final recommendation issued to sponsor and drug plans | 12-Dec-24 |
| Final recommendation posted | 07-Jan-25 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 03-Jan-25 |
| CDA-AMC review report(s) posted | 07-Apr-25 |
| Call for patient/clinician input open | 22-Apr-24 |
|---|---|
| Call for patient/clinician input closed | 17-Jun-24 |
| Submission received | 31-Jul-24 |
| Submission accepted | 15-Aug-24 |
| Review initiated | 16-Aug-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 01-Nov-24 |
| Deadline for sponsors comments | 13-Nov-24 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 06-Dec-24 |
| Expert committee meeting (initial) | 18-Dec-24 |
| Draft recommendation issued to sponsor | 08-Jan-25 |
| Draft recommendation posted for stakeholder feedback | 16-Jan-25 |
| End of feedback period | 31-Jan-25 |
| Final recommendation issued to sponsor and drug plans | 13-Feb-25 |
| Final recommendation posted | 04-Mar-25 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 28-Feb-25 |
| CDA-AMC review report(s) posted | 18-Jun-25 |
| Call for patient/clinician input open | 22-Apr-24 |
|---|---|
| Call for patient/clinician input closed | 17-Jun-24 |
| Submission received | 04-Jun-24 |
| Submission accepted | 18-Jun-24 |
| Review initiated | 19-Jun-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 06-Sep-24 |
| Deadline for sponsors comments | 17-Sep-24 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 10-Oct-24 |
| Draft recommendation issued to sponsor | 05-Nov-24 |
| Draft recommendation posted for stakeholder feedback | 21-Nov-24 |
| Clarification: - Posting of draft recommendation postponed from 14-Nov-2024 to 21-Nov-2024 | |
| End of feedback period | 05-Dec-24 |
| Final recommendation issued to sponsor and drug plans | 17-Dec-24 |
| Final recommendation posted | 10-Jan-25 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 08-Jan-25 |
| CDA-AMC review report(s) posted | 05-May-25 |
| Call for patient/clinician input open | 08-Mar-23 |
|---|---|
| Call for patient/clinician input closed | 02-May-23 |
| Clarification: - Patient input submission received from Lymphoma Canada | |
| Submission received | 18-Apr-24 |
| Submission accepted | 03-May-24 |
| Review initiated | 06-May-24 |
| Expert committee meeting (initial) | 10-Jul-24 |
| Draft recommendation issued to sponsor | 24-Jul-24 |
| Draft recommendation posted for stakeholder feedback | 01-Aug-24 |
| End of feedback period | 16-Aug-24 |
| Final recommendation issued to sponsor and drug plans | 29-Aug-24 |
| Final recommendation posted | 17-Sep-24 |
| CADTH review report(s) posted | 17-Dec-24 |
| Call for patient/clinician input open | April 10, 2024 |
|---|---|
| Call for patient/clinician input closed | June 03, 2024 |
| Submission received | May 22, 2024 |
| Submission accepted | June 05, 2024 |
| Review initiated | June 06, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | August 21, 2024 |
| Deadline for sponsors comments | August 30, 2024 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | September 26, 2024 |
| Draft recommendation issued to sponsor | October 23, 2024 |
| Draft recommendation posted for stakeholder feedback | October 31, 2024 |
| End of feedback period | November 15, 2024 |
| Final recommendation issued to sponsor and drug plans | November 28, 2024 |
| Final recommendation posted | December 16, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | December 12, 2024 |
| CDA-AMC review report(s) posted | March 27, 2025 |
| Call for patient/clinician input open | April 09, 2024 |
|---|---|
| Call for patient/clinician input closed | June 03, 2024 |
| Submission received | May 22, 2024 |
| Submission accepted | June 05, 2024 |
| Review initiated | June 06, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | August 23, 2024 |
| Deadline for sponsors comments | September 04, 2024 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | September 26, 2024 |
| Draft recommendation issued to sponsor | October 23, 2024 |
| Draft recommendation posted for stakeholder feedback | October 31, 2024 |
| End of feedback period | November 15, 2024 |
| Final recommendation issued to sponsor and drug plans | November 29, 2024 |
| Final recommendation posted | December 17, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | December 13, 2024 |
| CDA-AMC review report(s) posted | March 24, 2025 |
| Call for patient/clinician input open | 04-Apr-24 |
|---|---|
| Call for patient/clinician input closed | 03-Jun-24 |
| Submission received | 10-May-24 |
| Submission accepted | 30-May-24 |
| Clarification: - Submission was not accepted for review on 27-May-2024 | |
| Review initiated | 31-May-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 04-Sep-24 |
| Deadline for sponsors comments | 13-Sep-24 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 10-Oct-24 |
| Expert committee meeting (initial) | 23-Oct-24 |
| Draft recommendation issued to sponsor | 06-Nov-24 |
| Draft recommendation posted for stakeholder feedback | 14-Nov-24 |
| End of feedback period | 28-Nov-24 |
| Clarification: - Reconsideration: major revisions requested by sponsor | |
| Expert committee meeting | 26-Feb-25 |
| Draft recommendation issued to sponsor | 11-Mar-25 |
| Draft recommendation posted for stakeholder feedback | 20-Mar-25 |
| End of feedback period | 03-Apr-25 |
| Final recommendation issued to sponsor and drug plans | 16-Apr-25 |
| Final recommendation posted | 06-May-25 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 02-May-25 |
| CDA-AMC review report(s) posted | 14-Jul-25 |
We are testing a new approach that brings the societal perspective to our economic evaluation of certain new drugs.
| Call for patient/clinician input open | March 28, 2024 |
|---|---|
| Call for patient/clinician input closed | May 21, 2024 |
| Submission received | May 22, 2024 |
| Submission accepted | June 05, 2024 |
| Review initiated | June 06, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | August 21, 2024 |
| Deadline for sponsors comments | August 30, 2024 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | September 26, 2024 |
| Expert committee meeting (initial) | October 09, 2024 |
| Draft recommendation issued to sponsor | October 22, 2024 |
| Draft recommendation posted for stakeholder feedback | October 31, 2024 |
| End of feedback period | November 15, 2024 |
| Final recommendation issued to sponsor and drug plans | November 27, 2024 |
| Final recommendation posted | December 13, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | December 11, 2024 |
| CDA-AMC review report(s) posted | April 04, 2025 |